Novel assay methods for cancer patient derived organoids
This poster presents results from semi-automated PDO assays using a Pu•MA System coupled with high-content imaging.
- Capabilities of a novel automated organoid assay system that performs complex protocols with 3D cell models in an incubator environment.
- Patient-derived organoids derived from primary tumors were assayed for compound response using high resolution confocal imaging of cell surface markers and viability stains for Live/Dead.
- The ability to analyze spheroids and organoids in situ in order to capture toxicity information and perform functional assays shows great promise for disease modeling.